EXPERIENCE OF USING THE DRUG SELEXIPAG IN THE TREATMENT OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

被引：0
|
作者：
Karelkina, E. V. [1 ]
Goncharova, N. S. [1 ]
Simakova, M. A. [1 ]
Moiseeva, O. M. [1 ]
机构：
[1] FGBU Natl Med Res Ctr, St Petersburg, Russia
来源：
KARDIOLOGIYA | 2020年 / 60卷 / 04期
关键词：
PROSTACYCLIN-RECEPTOR AGONIST;
D O I：
10.18087/cardio.2020.4.n1026
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：36 / 42
页数：6
相关论文
共 50 条
  • [31] Real-World Dosing and Titration of Selexipag in Patients with Pulmonary Arterial Hypertension in the SPHERE Registry (SelexiPag: tHe UsErs dRug rEgistry): Interim Analysis
    Chakinala, M. M.
    Kim, N. H.
    Chin, K. M.
    Farber, H. W.
    Highland, K. B.
    Hemnes, A.
    Zhao, C.
    Keating, M.
    Hartline, B.
    McLaughlin, V. V.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [32] Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
    Simonneau, Gerald
    Torbicki, Adam
    Hoeper, Marius M.
    Delcroix, Marion
    Karlocai, Kristof
    Galie, Nazzareno
    Degano, Bruno
    Bonderman, Diana
    Kurzyna, Marcin
    Efficace, Michela
    Giorgino, Ruben
    Lang, Irene M.
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (04) : 874 - 880
  • [33] Functional Outcomes Of Selexipag Versus Inhaled Treprostinil For The Treatment Of Pulmonary Arterial Hypertension
    Pallazola, V. A.
    Visovatti, S.
    McLaughlin, V.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [34] The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
    Rosenkranz, Stephan
    Channick, Richard
    Chin, Kelly M.
    Jenner, Bartosz
    Gaine, Sean
    Galie, Nazzareno
    Ghofrani, Hossein-Ardeschir
    Hoeper, Marius M.
    McLaughlin, Vallerie V.
    Du Roure, Camille
    Rubin, Lewis J.
    Sitbon, Olivier
    Tapson, Victor
    Lang, Irene M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (01) : 205 - 214
  • [35] Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension
    Dong, Wenxing
    Zhang, Zhe
    Chu, Mingming
    Gu, Peng
    Hu, Min
    Liu, Lulu
    Huang, Jingbin
    Zhang, Rong
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [36] Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
    Gaine, Sean
    Chin, Kelly
    Coghlan, Gerry
    Channick, Richard
    Di Scala, Lilla
    Galie, Nazzareno
    Ghofrani, Hossein-Ardeschir
    Lang, Irene M.
    McLaughlin, Vallerie
    Preiss, Ralph
    Rubin, Lewis J.
    Simonneau, Gerald
    Sitbon, Olivier
    Tapson, Victor F.
    Hoeper, Marius M.
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50 (02)
  • [37] COST-EFFECTIVENESS OF SELEXIPAG FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Beaudet, A.
    Zervoudaki, A.
    Lamprou, C.
    Maniadakis, N.
    VALUE IN HEALTH, 2017, 20 (09) : A645 - A645
  • [38] Selexipag in pulmonary arterial hypertension: a comprehensive review.
    Dakwa, David S.
    Mella, Lisa
    Mella, Natalie
    Poulakos, Mara N.
    PHARMACOTHERAPY, 2016, 36 (12): : E301 - E301
  • [39] Safety concerns regarding selexipag in pulmonary arterial hypertension
    Greene, Rebecca A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (07) : 419 - 420
  • [40] Rosacea induced by selexipag in a patient with pulmonary arterial hypertension
    Dominguez-Santas, Miguel
    Diaz-Guimaraens, Borja
    Burgos-Blasco, Patricia
    Ortega-Quijano, Daniel
    Suarez-Valle, Ana
    Saceda-Corralo, David
    DERMATOLOGIC THERAPY, 2020, 33 (06)
12345